title: [Cellular therapy of diabetes: focus on the latest developments].
abstract: Islet transplantation has set the ground for diabetes cell therapy and is still undergoing various developments that might improve clinical outcomes. Alternative sources for β-cell replacement strategies are now led by human pluripotent stem cells that demonstrate near-normal β-cell features after in vitro differentiation and which can reverse diabetes in mice. Yet, their propensity for tumor formation is still unresolved. The adult pancreas is suggested as a reservoir of facultative progenitors that could represent adequate candidates for β-cell engineering, either in vivo through pharmacological treatment or after expansion in culture. This review focuses on the latest developments in protocols aiming at de novo production of functional β cells.
authors.affiliation: Laboratoire de pédiatrie, institut de recherche expérimentale et clinique, université catholique de Louvain, 1000 Bruxelles, Belgique - Unité d'endocrinologie pédiatrique, cliniques universitaires Saint Luc, université catholique de Louvain, 1000 Bruxelles, Belgique.
authors.forename: Philippe A
authors.initials: PA
authors.lastname: Lysy
mesh_terms: D000328:Adult; D000818:Animals; D002454:Cell Differentiation / Q000502:physiology; D064987:Cell- and Tissue-Based Therapy / Q000379:methods / Q000639:trends*; D003920:Diabetes Mellitus / Q000628:therapy*; D006801:Humans; D050417:Insulin-Secreting Cells / Q000637:transplantation; D016381:Islets of Langerhans Transplantation / Q000379:methods / Q000502:physiology; D051379:Mice; D010179:Pancreas / Q000166:cytology / Q000502:physiology; D039904:Pluripotent Stem Cells / Q000502:physiology / Q000637:transplantation; D012038:Regeneration